Our top pick for
DZS Inc is a communication equipment business based in the US. DZS shares (DZSI) are listed on the NASDAQ and all prices are listed in US Dollars. DZS employs 830 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$11.24|
|52-week range||$9.30 - $23.48|
|50-day moving average||$12.91|
|200-day moving average||$16.17|
|Wall St. target price||$21.63|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-1.70|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-15)||-5.07%|
|1 month (2021-09-24)||-11.01%|
|3 months (2021-07-23)||-41.52%|
|6 months (2021-04-23)||-22.75%|
|1 year (2020-10-23)||7.56%|
|2 years (2019-10-24)||51.08%|
|3 years (2018-10-24)||13.12|
|5 years (2016-10-24)||970.48%|
Valuing DZS stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of DZS's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
DZS's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $1.4 million.
The EBITDA is a measure of a DZS's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||$346.4 million|
|Gross profit TTM||$96.9 million|
|Return on assets TTM||-4.66%|
|Return on equity TTM||-35.29%|
|Market capitalisation||$322 million|
TTM: trailing 12 months
There are currently 297,975 DZS shares held short by investors – that's known as DZS's "short interest". This figure is 3% up from 289,174 last month.
There are a few different ways that this level of interest in shorting DZS shares can be evaluated.
DZS's "short interest ratio" (SIR) is the quantity of DZS shares currently shorted divided by the average quantity of DZS shares traded daily (recently around 70946.428571429). DZS's SIR currently stands at 4.2. In other words for every 100,000 DZS shares traded daily on the market, roughly 4200 shares are currently held short.
However DZS's short interest can also be evaluated against the total number of DZS shares, or, against the total number of tradable DZS shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case DZS's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 DZS shares in existence, roughly 10 shares are currently held short) or 0.0175% of the tradable shares (for every 100,000 tradable DZS shares, roughly 18 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against DZS.
Find out more about how you can short DZS stock.
We're not expecting DZS to pay a dividend over the next 12 months.
DZS's shares were split on a 1:5 basis on 28 February 2017. So if you had owned 5 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your DZS shares – just the quantity. However, indirectly, the new 400% higher share price could have impacted the market appetite for DZS shares which in turn could have impacted DZS's share price.
Over the last 12 months, DZS's shares have ranged in value from as little as $9.3 up to $23.48. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while DZS's is 1.3577. This would suggest that DZS's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
DZS Inc. provides network access solutions and communications platforms for service provider and enterprise networks in the Americas, Europe, the Middle East, Africa, and Asia. It offers mobile transport products, including standard Ethernet/IP or multiprotocol label switching interfaces and interoperate to mobile operators that enables them to upgrade their mobile fronthaul/backhaul systems and migrate to 5G and beyond; broadband access products, which consists of switching and routing products to carriers and service providers to connect residential and business customers; and connected premises products, comprising of indoor/outdoor optical network terminal gateways. The company also provides software and services, which consists of software defined networking orchestration solutions, network function virtualization, and professional and technical support services. It has a strategic partnership with Quanta Cloud Technology; and Plume Design, Inc. The company was formerly known as DASAN Zhone Solutions, Inc. and changed its name to DZS Inc.
Steps to owning and managing ProShares Bitcoin Strategy ETF units.
Everything we know about the The Real Good Food Company IPO, plus information on how to buy in.
Everything we know about the Lulu’s Fashion Lounge Holdings IPO, plus information on how to buy in.
Everything we know about the Allarity Therapeutics IPO, plus information on how to buy in.
Everything we know about the Jupiter Neurosciences IPO, plus information on how to buy in.
Everything we know about the Mainz Biomed IPO, plus information on how to buy in.
Everything we know about the Progressive Care IPO, plus information on how to buy in.
Everything we know about the Desert Peak Minerals IPO, plus information on how to buy in.
Everything we know about the Vaxxinity IPO, plus information on how to buy in.
Everything we know about the Entrada Therapeutics IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.